On Oct 04, major Wall Street analysts update their ratings for $CME Group (CME.US)$, with price targets ranging from $180 to $275.
Goldman Sachs analyst Alexander Blostein maintains with a sell rating, and adjusts the target price from $201 to $198.
BofA Securities analyst Craig Siegenthaler maintains with a sell rating, and adjusts the target price from $177 to $180.
Citi analyst Christopher Allen maintains with a buy rating, and adjusts the target price from $240 to $250.
UBS analyst Alex Kramm maintains with a buy rating, and adjusts the target price from $250 to $275.
Furthermore, according to the comprehensive report, the opinions of $CME Group (CME.US)$'s main analysts recently are as follows:
Lower interest rates and a slow recovery in deal activity present downside risks across most capital markets stocks as Q3 reports approach. Although faster rate cuts and stronger equity markets have encouraged risk-on behavior, sluggish deal rates persist as a headwind for many alternative managers amidst valuations that are considered very high. Traditional managers have seen organic growth worsen in the third quarter, and lower interest rates pose a significant threat to the earnings of brokers and wealth managers. Exchanges and trust banks are seen as relatively positive aspects in the context of Q3 outcomes.
The company's trading activity in Q3 has been characterized as 'robust'. Looking forward, the volume outlook is perceived as solid, and the company is expected to be well positioned to benefit from its asset diversity and the depth of liquidity on its platform.
Here are the latest investment ratings and price targets for $CME Group (CME.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月4日，多家華爾街大行更新了$芝加哥商品交易所 (CME.US)$的評級，目標價介於180美元至275美元。
高盛集團分析師Alexander Blostein維持賣出評級，並將目標價從201美元下調至198美元。
美銀證券分析師Craig Siegenthaler維持賣出評級，並將目標價從177美元上調至180美元。
花旗分析師Christopher Allen維持買入評級，並將目標價從240美元上調至250美元。
瑞士銀行分析師Alex Kramm維持買入評級，並將目標價從250美元上調至275美元。
此外，綜合報道，$芝加哥商品交易所 (CME.US)$近期主要分析師觀點如下：
低利率和交易活動復甦緩慢使得大多數資本市場股票面臨下行風險，在第三季度報告即將發佈之際。儘管更快的利率降低和更強勁的股票市場鼓勵了風險偏好，但低迷的交易量仍然作爲衆多另類投資者的潛在阻力，尤其是在估值被認爲是非常高的情況下。傳統投資者在第三季度看到有機增長惡化，而低利率對券商和财富管理者的收益構成了重大威脅。交易所和信託銀行被視爲第三季度業績相對積極的方面。
該公司在第三季度的交易活動被描述爲"強勁"。展望未來，交易量前景被視爲穩固，公司有望從其資產多樣性和平台流動性的深度中受益。
以下爲今日4位分析師對$芝加哥商品交易所 (CME.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
